Lastly, TRELEGY ELLIPTA represents a once-daily combination medicine bringing together an ICS, LAMA, and LABA into one inhaler device. Like RELVAR/BREO ELLIPTA, it is primarily used for managing COPD symptoms. It combines a long-acting muscarinic antagonist (LAMA) known as umeclidinium bromide (UMEC) with a LABA called VI. This medication is used for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.ĪNORO ELLIPTA is another once-daily medication developed by Innoviva. RELVAR/BREO ELLIPTA is a once-daily combination medicine comprised of a long-acting beta2-adrenergic agonist (LABA) called vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate. The company’s product portfolio includes several notable medicines such as RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA. is an American biotechnology company that specializes in the development and commercialization of pharmaceutical products both domestically and internationally. This stake is estimated to be worth $1,388,000 as per the most recent filing. According to the disclosure filed with the Securities and Exchange Commission (SEC), the company now owns 123,377 shares of Innoviva stock, after acquiring an additional 27,934 shares during the period. by 29.3% during the first quarter of this year.
On September 5, 2023, it was reported that WINTON GROUP Ltd had increased its holdings in Innoviva, Inc.
0 kommentar(er)
